I'm A Patient
I'm A Provider
Direct Answer
Canada has several safe, evidence-based management options for dry age-related macular degeneration (AMD). These include regular monitoring with retinal imaging, lifestyle modifications, such as smoking cessation and dietary improvement, AREDS2 nutritional supplementation for patients with intermediate or advanced disease, and authorized device-based therapy for improving visual function in eligible patients. Each option has been assessed through published evidence and, where applicable, formal regulatory review.1
Safety in a clinical context does not mean zero risk in all circumstances. It means that the benefit-risk profile of a treatment has been evaluated through a recognized process and found acceptable for authorized use. Patients should discuss individual safety considerations with their eye care provider, as personal health history and disease stage affect which options are most appropriate.2
What Safety Means for Dry AMD Treatments
When patients ask about safe treatments for macular degeneration, they are usually asking one of several related questions: Will this hurt? Will it cause side effects? Has it been tested? Is it Health Canada–authorized? These are all legitimate questions and the answers vary by intervention.1
In a regulatory context, safety assessment for a treatment involves evaluating whether adverse events occurred in clinical trials, how serious they were, how frequently they occurred, and whether they were caused by the treatment rather than by the underlying disease or other factors. Regulatory bodies such as Health Canada use this assessment to determine whether a treatment’s benefits outweigh its risks for a specific patient population and clinical purpose.3
Patients who have previously experienced invasive eye treatments, such as anti-VEGF injections for wet AMD, sometimes approach dry AMD treatment options with heightened concern about procedural risk. It is worth noting that the management options for dry AMD are substantially less invasive than those for wet AMD: none involve injections into the eye, and most carry minimal procedural risk.
Safety Profile of Each Dry AMD Management Option in Canada
Monitoring with Retinal Imaging
Regular monitoring using optical coherence tomography (OCT) is noninvasive and carries no direct clinical risk. The imaging process involves a brief scan of the macula using light waves and does not require eye drops in most settings, though dilated fundus examination may be recommended alongside imaging in some clinical protocols.1
The benefit of monitoring is indirect but significant: it enables early detection of disease changes and allows timely clinical decisions. The risk of inadequate monitoring is significant, particularly the risk of missing conversion from dry to wet AMD, which requires urgent treatment and can cause rapid, irreversible vision loss if not detected and treated promptly.
Lifestyle Modifications
Lifestyle changes recommended for AMD risk reduction, including stopping smoking, improving diet, protecting eyes from UV exposure, and managing cardiovascular health, typically carry no clinical risk and are broadly beneficial. Stopping smoking is the single most impactful modifiable risk factor for AMD progression and has well-established systemic health benefits beyond its effect on AMD.4
These modifications do not require clinical supervision in the same way a drug or device does, but they should be discussed with a health professional to ensure they are implemented safely and sustainably for the individual patient.
AREDS2 Supplementation
AREDS2 supplements are generally well tolerated and have a strong safety record in the populations studied. The most important safety consideration is that formulations containing beta-carotene are contraindicated in current or former smokers due to an increased risk of lung cancer, a finding established in large randomized trials. The AREDS2 formulation, which replaced beta-carotene with lutein and zeaxanthin, is the recommended version for most patients and does not carry this risk.1
High-dose zinc in the AREDS2 formula can cause gastrointestinal discomfort in some patients, particularly at the beginning of supplementation. Patients with conditions affecting zinc metabolism should discuss this with their physician. AREDS2 supplements are not appropriate for patients with early dry AMD where the evidence for benefit is weaker or for those who have not had their AMD stage confirmed. A clinician should determine eligibility before supplementation begins.1
Authorized Device-Based Therapy
Device-based therapy for dry AMD is noninvasive. Treatment involves microcurrents delivered through ultrasound gel applied to closed eyelids using a specialized headset device. There are no injections, no incisions, and no requirement for anesthesia or eye dilation. Patients typically find the procedure comfortable and can return to normal activity immediately after a session.2
MacuMira is a Health Canada–authorized treatment device indicated to improve visual function in patients with dry AMD. In its published randomized sham-controlled clinical trial, zero device-related serious adverse events were recorded. This safety record has been maintained in real-world use, with more than 21,000 treatments delivered across hundreds of clinics in 3 countries with no device-related serious adverse events reported since launch.2
MacuMira holds a Health Canada Medical Device Licence for dry AMD. Health Canada authorization requires demonstration that the device meets rigorous safety and quality standards for its authorized indication. MacuMira is not indicated for wet AMD and treatment is for use under the supervision of a licensed eye care professional.23
Patients with implanted electronic devices such as pacemakers or cochlear implants should discuss this with their eye care provider before beginning device-based therapy, as the treating clinician will assess whether any contraindication applies. A clinical eligibility assessment is required before treatment begins.2
What to Be Cautious About: Unregulated Products
Not all products marketed as treatments or therapies for macular degeneration in Canada hold Health Canada authorization. Some supplements, wellness devices and alternative therapies use language suggesting benefit for AMD without having been assessed through formal regulatory review. The absence of Health Canada authorization does not mean a product is necessarily harmful, but it does mean its safety and efficacy have not been independently evaluated to the standard required for a medical claim.3
Patients who encounter products online or in health food stores claiming to treat or improve macular degeneration should ask their eye care provider whether the product is regulated and what evidence supports its use. The same caution applies to devices sold for home use without regulatory authorization: the safety profile of a wellness device is not equivalent to that of a medically authorized device that has undergone a formal review process.
A useful question to ask of any product is: “Is this authorized by Health Canada as a Class II medical device for dry AMD?” If the answer is no, the safety and efficacy evidence base differs in character from that required for a regulated product.
How to Evaluate Safety when Considering a New Dry AMD Treatment
- Ask whether the treatment holds Health Canada authorization and for which specific indication it is authorized.3
- Ask whether a published randomized controlled trial has been conducted and whether adverse event data is fully reported in that trial.2
- Ask about the real-world safety record: how many treatments have been delivered and has any adverse event data been submitted to Health Canada?
- Discuss your personal health history with your eye care provider, including any implanted devices or medications that might affect which options are appropriate for you.1
- For supplements, confirm your AMD stage with a clinician before starting and clarify whether your specific formulation is appropriate given your smoking history.1
- Ask whether the treatment has been evaluated specifically in patients similar to you in terms of AMD stage and baseline visual acuity.
Key takeaway
Safe, evidence-based dry AMD management options are available in Canada at every stage of disease. Monitoring and lifestyle modification carry minimal procedural risk. AREDS2 supplementation is well tolerated with specific contraindications that should be reviewed with a clinician. Health Canada–authorized device-based therapy with MacuMira is noninvasive, has recorded zero device-related serious adverse events across clinical trials and more than 21,000 real-world treatments, and holds a Health Canada Medical Device Licence for dry AMD.
Patients should ask specifically whether any product they are considering holds Health Canada authorization and review the published safety evidence with their eye care provider. MacuMira is for use under the supervision of a licensed eye care professional and is not indicated for wet AMD.
Disclaimer
This article is for educational purposes only and is not a substitute for professional medical advice. Patients should discuss all management options, including their individual safety considerations, with a qualified eye care professional before making treatment decisions.
Glossary
Health Canada Medical Device Licence: Regulatory authorization confirming a medical device meets Canadian safety and efficacy standards for its authorized indication. Required for clinical use of any regulated medical device in Canada.
MacuMira: A Health Canada–authorized treatment device indicated to improve visual function in patients with dry AMD, delivered via low-level electrical stimulation in a clinical setting under the supervision of a licensed eye care professional. Not indicated for wet AMD.
AREDS2 formula: A nutritional supplement combination including lutein, zeaxanthin, vitamin C, vitamin E and zinc. Reduces progression risk to advanced AMD by approximately 25% in eligible patients. Not appropriate for patients with early dry AMD or for current/former smokers using the beta-carotene formulation.
Dry AMD: A progressive retinal condition affecting the macula. The most common form of AMD. Distinct from wet AMD in pathophysiology and management.
Wet AMD: A form of AMD involving abnormal blood vessel growth beneath the retina. Treated with anti-VEGF injections. MacuMira is not indicated for wet AMD.
Optical coherence tomography (OCT): A noninvasive retinal imaging technology producing cross-sectional images of the macula. Standard for AMD staging and monitoring.
Sham-controlled trial: A clinical trial in which the control group receives a procedure mimicking the active intervention except for the active component. The appropriate design for assessing device safety and efficacy.
Post-market surveillance: Ongoing monitoring of a treatment’s safety and performance after regulatory authorization through adverse event reporting and real-world outcome tracking.
Geographic atrophy: An advanced stage of dry AMD in which large areas of retinal pigment epithelium and photoreceptors have degenerated irreversibly.
Beta-carotene: A form of vitamin A included in some older AMD supplement formulations. Contraindicated in current and former smokers due to elevated lung cancer risk. The AREDS2 formulation replaces it with lutein and zeaxanthin.
References
1. Age-Related Macular Degeneration. National Eye Institute, National Institutes of Health. Last reviewed November 2023. Accessed June 2026. https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration.
2. Evaluation of visual acuity in dry AMD patients after microcurrent electrical stimulation. Parkinson KM, Sayre EC, Tobe SW. International Journal of Retina and Vitreous. Published May 2023. Accessed June 2026. https://macumira.com/wp-content/uploads/2025/07/MacuMira-Clinical-Trial.pdf.
3. Medical Device Licences. Health Canada. Date not listed. Accessed June 2026. https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/licences.html.
4. Understanding Macular Degeneration. American Academy of Ophthalmology. Published November 2025. Accessed June 2026. https://www.aao.org/eye-health/diseases/amd-macular-degeneration.
5. Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration: The Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial. AREDS2 Research Group. JAMA. Published May 15, 2013. Accessed June 2026. https://jamanetwork.com/journals/jama/fullarticle/1684847.
